CD7 expression in malignant pleural mesothelioma

Our plain-English summary of CD7 expression in malignant pleural mesothelioma, by S. Hibi, Y. Kataoka, N. Fujita, et al (Japanese Journal of Cancer Research, 1992).

The study

• Authors: S. Hibi, Y. Kataoka, N. Fujita, H. Okabe, K. Yoshikawa, M. Seto, R. Ueda, S. Imashuku
• Journal: Japanese Journal of Cancer Research
• Published: 1992;83(7):680-3
• Type of article: Case report
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

CD7 antigen was found to be expressed on malignant mesothelioma arising from the right pleura in a 15-year-old girl not only by immunostaining using monoclonal antibodies, but also by Northern blot analysis. The level of expression in this tumor was comparable to those in T-cell lines, Jurkat and CCRF-CEM. Cytogenetic analysis of the tumor showed hypodiploidy (n = 43). CD7 has been regarded as one of the hematopoietic cell markers selectively expressed on the majority of T cells and multipotential stem cells. To our knowledge, this is the first report of a non-hematopoietic tumor expressing CD7.

In plain English

This was a case report of a 15-year-old girl seen in February 1991 with right chest pain. The article states she had no history of exposure to asbestos. A biopsy led to a diagnosis of malignant pleural mesothelioma (localized fibrous, malignant). The tumor cells were positive for vimentin and CD56. The report centered on CD7, a marker the authors describe as thought to be specific to blood-forming cells. The tumor cells strongly expressed CD7. This was shown with two monoclonal antibodies and by Northern blot, at a level similar to two CD7-positive T-cell lines (Jurkat and CCRF-CEM). The other blood-cell markers tested, including CD45, were negative. Chromosome analysis showed hypodiploidy (43 chromosomes). After combination chemotherapy, the tumor shrank and almost disappeared within ten months. The authors concluded that, to their knowledge, this was the first report of a non-blood-cell tumor expressing CD7. They noted that neuroblastoma had been reported negative for CD7, that they found no literature examining CD7 in any other solid tumors, and that CD7 might have been found in such tumors if looked for.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: case report (rapid communication) of a single patient
• Who was studied: one 15-year-old girl referred to the authors' hospital on February 14, 1991 with right chest pain
• Exposure: No asbestos exposure: the patient had no history of exposure to asbestos. The study examined whether the tumor carried the CD7 marker, not asbestos exposure.
• Main results:
  • The patient's tumor was diagnosed as malignant pleural mesothelioma (localized fibrous, malignant)
  • The tumor cells were positive for vimentin and CD56
  • The tumor cells strongly expressed CD7, confirmed with two monoclonal antibodies (3A1, T55) and by Northern blot analysis
  • CD7 messenger RNA in the tumor was detected at a similar intensity to that in the CD7-positive T-cell lines Jurkat and CCRF-CEM
  • None of the other blood-cell markers tested on the tumor (CD2, CD3, CD4, CD5, CD8, CD10, CD19, CD20, HLA-DR, CD45) was positive
  • Chromosome analysis of the tumor showed hypodiploidy (43 chromosomes)
  • After chemotherapy, the patient's tumor mass decreased and almost disappeared in ten months
• The authors' conclusion: The authors concluded that, to their knowledge, this was the first report of a non-hematopoietic (non-blood-cell) tumor expressing CD7
• Limitations the authors state:
  • Apart from a reported neuroblastoma study that found CD7 negative, the authors found no literature examining CD7 expression on any other solid tumors
  • The authors noted that CD7 might have been detected in solid tumors if they had been examined

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Malignant Mesothelioma, Pleura, Monoclonal, STEM.

Related studies

• Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A — P. Wu, F. Hyodoh, et al. (2005)
• Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications — L. Calabrò, L. Sigalotti, et al. (2011)
• Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma — S. Inaguma, J. Lasota, et al. (2018)
• Analysis on the co-localization of asbestos bodies and Fas or CD163 expression in asbestos lung tissue by in-air micro-pixe — S. Matsuzaki, Y. Shimizu, et al. (2010)
• Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications — L. Calabrò, R. Danielli, et al. (2010)
• Identification of cancer stem cell markers in human malignant mesothelioma cells — F.I. Ghani, H. Yamazaki, et al. (2011)

Browse more research in Japanese Journal of Cancer Research, or return to medical research.